Cue Biopharma (CUE)
(Delayed Data from NSDQ)
$1.63 USD
+0.04 (2.52%)
Updated May 31, 2024 04:00 PM ET
After-Market: $1.63 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.63 USD
+0.04 (2.52%)
Updated May 31, 2024 04:00 PM ET
After-Market: $1.63 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Zacks News
5 Biotech Stocks That Have More Than Doubled This Year
by Ekta Bagri
The biotech sector has had a good run in 2019 on the back of ongoing M&A activities and positive pipeline updates.
The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech
5 Biotech Stocks Up More Than 100% This Year So Far
by Indrajit Bandyopadhyay
The biotech sector recovers on the back of rising M&A activities and pipeline successes in 2019 after a dismal 2018. Here we discuss five biotech companies recording impressive growth.
Here's Why Cue Biopharma, Inc. (CUE) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Cue Biopharma, Inc. (CUE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Cue Biopharma, Inc. (CUE) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Cue Biopharma, Inc. (CUE).
What Makes Cue Biopharma, Inc. (CUE) a New Strong Buy Stock
by Zacks Equity Research
Cue Biopharma, Inc. (CUE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).